Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development
April 17 2017 - 9:00AM
Business Wire
Experienced executive addition with proven
leadership and drug development expertise in emerging fields of
medicine
Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical
company developing innovative cellular immunotherapies for the
treatment of cancer, today announced it has appointed Sunil
Agarwal, M.D., as President of Research and Development. With Dr.
Agarwal’s appointment, Juno will bring Research and Development
under one leader responsible for the execution of Juno’s drug
development pipeline, integration of translational insights into
ongoing programs, and the prioritization of research and
development initiatives. Prior to joining Juno, Dr. Agarwal’s last
industry role was Chief Medical Officer, Executive Vice President
at Ultragenyx.
“Sunil is a strong strategic thinker and experienced drug
developer who will be a great addition to our executive team,” said
Hans Bishop, President and CEO of Juno. “He has an established
track record of bringing innovative therapies to market,
demonstrated by the breadth and quality of the programs he has led.
His drug development experience, instincts, and scientific judgment
will be important for our next phase of growth, and we will benefit
from his experience and insight in both our strategy and
execution.”
Prior to his tenure at Ultragenyx, Dr. Agarwal worked in several
senior leadership roles at Genentech, Inc., most recently as Senior
Vice President, Global Development Head, Ophthalmology, Metabolism,
Neuroscience, Immunology and Infectious Diseases. He was
responsible for the global development of programs in these areas
from proof of concept (PoC) through Phase IV. He was also a member
of both the Genentech Research and Early Development (gRED) and
Pharma Research and Early Development (pRED) committees, which
defined the strategy of all molecules from pre-Investigational New
Drug through PoC in numerous therapeutic areas, including oncology.
He has led global approvals of multiple therapies and successfully
built and led large global development organizations in multiple
geographies. At Juno, Dr. Agarwal will report to Mr. Bishop and
will be a member of the firm’s Executive Committee.
“Transforming innovative science into meaningful medicines for
patients and building strong organizations fits very well with my
passion, experience, and expertise,” said Dr. Agarwal. “Engineered
cell and gene therapies have the potential to transform the
landscape of medicine over the coming decade, and Juno is well
positioned to be a leader in this era. I am delighted to join Juno
at this exciting time for the company, and I look forward to
partnering with the team on executing Juno’s vision.”
Dr. Agarwal obtained his bachelor of science in Neurobiology at
Cornell University and earned his medical degree from Tufts
University School of Medicine. He completed his residency at
Children's National Medical Center, Washington, D.C., and
subsequently joined the faculty at George Washington University
School of Medicine.
ABOUT JUNO
Juno Therapeutics is building a fully integrated
biopharmaceutical company focused on developing innovative cellular
immunotherapies for the treatment of cancer. Founded on the vision
that the use of human cells as therapeutic entities will drive one
of the next important phases in medicine, Juno is developing
cell-based cancer immunotherapies based on chimeric antigen
receptor and high-affinity T cell receptor technologies to
genetically engineer T cells to recognize and kill cancer. Juno is
developing multiple cell-based product candidates to treat a
variety of B-cell malignancies as well as solid tumors. Several
product candidates have shown compelling clinical responses in
clinical trials in refractory leukemia and lymphoma conducted to
date. Juno's long-term aim is to leverage its cell-based platform
to develop new product candidates that address a broader range of
cancers and human diseases. Juno brings together innovative
technologies from some of the world's leading research
institutions, including the Fred Hutchinson Cancer Research
Center, Memorial Sloan Kettering Cancer Center, Seattle
Children's Research Institute (SCRI), the University
of California, San Francisco, and The National
Cancer Institute. Juno Therapeutics has an exclusive
license to the St. Jude Children’s Research Hospital patented
technology for CD19-directed product candidates that use 4-1BB,
which was developed by Dario Campana, Chihaya Imai, and
St. Jude Children’s Research Hospital. Juno’s product
candidate JCAR017 was developed in collaboration with SCRI and
others.
FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933, and Section 21E of
the Securities Exchange Act of 1934, including statements regarding
Juno’s mission, progress, and business plans. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially from such forward-looking
statements, and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to, risks associated with: the
success, cost, and timing of Juno's product development activities
and clinical trials; Juno's ability to obtain regulatory approval
for and to commercialize its product candidates; Juno's ability to
establish a commercially-viable manufacturing process and
manufacturing infrastructure; regulatory requirements and
regulatory developments; success of Juno's competitors with respect
to competing treatments and technologies; Juno's dependence on
third-party collaborators and other contractors in Juno's research
and development activities, including for the conduct of clinical
trials and the manufacture of Juno's product candidates; Juno's
dependence on Celgene for the development and
commercialization outside of North
America and China of Juno’s CD19 product candidates
and any other product candidates for
which Celgene exercises an option; Juno’s dependence
on JW Therapeutics (Shanghai) Co., Ltd, over which Juno does
not exercise complete control, for the development and
commercialization of product candidates in China; Juno's
ability to obtain, maintain, or protect intellectual property
rights related to its product candidates; amongst others. For a
further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Juno's
business in general, see Juno's Annual Report on Form 10-K filed
with the Securities and Exchange Commission on March
1, 2017 and Juno’s other periodic reports filed with
the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Juno disclaims any
obligation to update these forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170417005240/en/
Juno TherapeuticsInvestor Relations:Nicole Keith,
206-566-5521nikki.keith@junotherapeutics.comorMedia:Christopher
Williams, 206-566-5660chris.williams@junotherapeutics.com
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From Aug 2024 to Sep 2024
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From Sep 2023 to Sep 2024